메뉴 건너뛰기




Volumn 23, Issue 6, 2012, Pages 380-390

Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents

Author keywords

acute coronary syndrome; atrial fibrillation; direct thrombin inhibitors; factor Xa inhibitors; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENYTOIN; PLACEBO; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN;

EID: 84864829605     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328356490a     Document Type: Review
Times cited : (4)

References (30)
  • 1
    • 0037022204 scopus 로고    scopus 로고
    • Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: Primary results of the CHAMP study
    • DOI 10.1161/hc0502.103329
    • Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105:557-563. (Pubitemid 34123428)
    • (2002) Circulation , vol.105 , Issue.5 , pp. 557-563
    • Fiore, L.D.1    Ezekowitz, M.D.2    Brophy, M.T.3    Lu, D.4    Sacco, J.5    Peduzzi, P.6
  • 2
    • 45349084183 scopus 로고    scopus 로고
    • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: Observations from the CRUSADE quality improvement initiative
    • DOI 10.1093/eurheartj/ehn126
    • Wang TY, Chen AY, Peterson ED, Becker RC, GiblerWB, Ohman EM, Roe MT. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. Eur Heart J 2008; 29:1103-1109. (Pubitemid 351844888)
    • (2008) European Heart Journal , vol.29 , Issue.9 , pp. 1103-1109
    • Wang, T.Y.1    Chen, A.Y.2    Peterson, E.D.3    Becker, R.C.4    Gibler, W.B.5    Ohman, E.M.6    Roe, M.T.7
  • 3
    • 84856046638 scopus 로고    scopus 로고
    • The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE)
    • Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, et al. The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2012; 28:48-53.
    • (2012) Can J Cardiol , vol.28 , pp. 48-53
    • Amad, H.1    Yan, A.T.2    Yan, R.T.3    Huynh, T.4    Gore, J.M.5    Montalescot, G.6
  • 4
    • 33645229796 scopus 로고    scopus 로고
    • Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients
    • Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27:519-526.
    • (2006) Eur Heart J , vol.27 , pp. 519-526
    • Andreotti, F.1    Testa, L.2    Biondi-Zoccai, G.G.3    Crea, F.4
  • 5
    • 79957598382 scopus 로고    scopus 로고
    • Combination warfarin-ASA therapy: Which patients should receive it, which patients should not, and why?
    • Douketis JD. Combination warfarin-ASA therapy: which patients should receive it, which patients should not, and why? Thromb Res 2011; 127:513-517.
    • (2011) Thromb Res , vol.127 , pp. 513-517
    • Douketis, J.D.1
  • 6
    • 71749093136 scopus 로고    scopus 로고
    • Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes
    • Depta JP, Cannon CP, Fonarow GC, Zhao X, PeacockWF, Bhatt DL. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol 2009; 104:1171-1178.
    • (2009) Am J Cardiol , vol.104 , pp. 1171-1178
    • Depta, J.P.1    Cannon, C.P.2    Fonarow, G.C.3    Zhao, X.4    Peacock, W.F.5    Bhatt, D.L.6
  • 8
    • 80053177375 scopus 로고    scopus 로고
    • Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective
    • Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106:572-584.
    • (2011) Thromb Haemost , vol.106 , pp. 572-584
    • Faxon, D.P.1    Eikelboom, J.W.2    Berger, P.B.3    Holmes, D.R.4    Bhatt, D.L.5    Moliterno, D.J.6
  • 9
    • 77958138432 scopus 로고    scopus 로고
    • Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes
    • Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 2010; 104:657-663.
    • (2010) Thromb Haemost , vol.104 , pp. 657-663
    • Depta, J.P.1    Bhatt, D.L.2
  • 10
    • 80053336306 scopus 로고    scopus 로고
    • New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome
    • Davis EM, Packard KA, Knezevich JT, Campbell JA. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011; 31:975-1016.
    • (2011) Pharmacotherapy , vol.31 , pp. 975-1016
    • Davis, E.M.1    Packard, K.A.2    Knezevich, J.T.3    Campbell, J.A.4
  • 11
    • 74949139434 scopus 로고    scopus 로고
    • The new oral anticoagulants
    • Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15-20.
    • (2010) Blood , vol.115 , pp. 15-20
    • Garcia, D.1    Libby, E.2    Crowther, M.A.3
  • 12
    • 77949534765 scopus 로고    scopus 로고
    • Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism
    • Yong CM, Boyle AJ. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. Curr Vasc Pharmacol 2010; 8:5-11.
    • (2010) Curr Vasc Pharmacol , vol.8 , pp. 5-11
    • Yong, C.M.1    Boyle, A.J.2
  • 13
    • 78650792758 scopus 로고    scopus 로고
    • Factor Xa and thrombin as targets for new oral anticoagulants
    • Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl 2):S5-S12.
    • (2011) Thromb Res , vol.127 , Issue.SUPPL. 2
    • Weitz, J.I.1
  • 14
    • 79957606320 scopus 로고    scopus 로고
    • The mechanism of action of rivaroxaban - An oral, direct Factor Xa inhibitor - Compared with other anticoagulants
    • Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res 2011; 127:497-504.
    • (2011) Thromb Res , vol.127 , pp. 497-504
    • Samama, M.M.1
  • 15
    • 67649562905 scopus 로고    scopus 로고
    • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
    • Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
    • (2009) Lancet , vol.374 , pp. 29-38
    • Mega, J.L.1    Braunwald, E.2    Mohanavelu, S.3    Burton, P.4    Poulter, R.5    Misselwitz, F.6
  • 17
    • 67649563209 scopus 로고    scopus 로고
    • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    • Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
    • (2009) Circulation , vol.119 , pp. 2877-2885
    • Alexander, J.H.1    Becker, R.C.2    Bhatt, D.L.3    Cools, F.4    Crea, F.5    Dellborg, M.6
  • 19
    • 80052232522 scopus 로고    scopus 로고
    • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial
    • Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781-2789.
    • (2011) Eur Heart J , vol.32 , pp. 2781-2789
    • Oldgren, J.1    Budaj, A.2    Granger, C.B.3    Khder, Y.4    Roberts, J.5    Siegbahn, A.6
  • 20
    • 84863142762 scopus 로고    scopus 로고
    • Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial
    • Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012; 125:669-676.
    • (2012) Circulation , vol.125 , pp. 669-676
    • Hohnloser, S.H.1    Oldgren, J.2    Yang, S.3    Wallentin, L.4    Ezekowitz, M.5    Reilly, P.6
  • 21
    • 84857021520 scopus 로고    scopus 로고
    • Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized Controlled Trials
    • Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized Controlled Trials. Arch Intern Med 2012; 172:397-402.
    • (2012) Arch Intern Med , vol.172 , pp. 397-402
    • Uchino, K.1    Hernandez, A.V.2
  • 24
  • 27
    • 55349085390 scopus 로고    scopus 로고
    • The top 4 advances in antithrombotic care in the last year
    • Turpie AG. The top 4 advances in antithrombotic care in the last year. Thromb Res 2008; 123 (Suppl 1):S2-S6.
    • (2008) Thromb Res , vol.123 , Issue.SUPPL. 1
    • Turpie, A.G.1
  • 29
    • 79958126202 scopus 로고    scopus 로고
    • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    • Eikelboom JW,Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
    • (2011) Circulation , vol.123 , pp. 2363-2372
    • Eikelboom, J.W.1    Wallentin, L.2    Connolly, S.J.3    Ezekowitz, M.4    Healey, J.S.5    Oldgren, J.6
  • 30
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
    • Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.
    • (2011) Circulation , vol.124 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3    Meijers, J.C.4    Buller, H.R.5    Levi, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.